Genetic disorders market is forecast to grow from $19.6 billion in 2016
to $47.7 billion in 2023, at a CAGR of 13.6%. This high level of growth will be
driven largely by orphan drugs for the treatment of rare genetic disorders.
Report titled “Global Genetic Disorders
Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted
Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and
Lysosomal Storage Disease” helps the reader to gain more insights in the
area of genetic disorders covering aspects such as Symptoms, Diagnosis,
Treatment, Key products, clinical trials, company analysis and future forecast.
As rare genetic disorders are often debilitating or fatal, with low
prevalence, sponsors are willing to pay for some of the most expensive
treatments in the pharmaceutical industry. This contributes to high sales
revenue, despite small patient groups. Orphan drugs are able to generate high
revenue because of developmental incentives such as marketing exclusivity, which
allows for longer periods before generics and biosimilars can enter the market.
Furthermore, other incentives such as tax credits and accelerated approval
lower the developmental costs faced by pharmaceutical companies, reducing the
inherent financial risks involved and increasing the likelihood of recouping
developmental costs from product sales.
The genetic disorders market has a strong presence of specialized
companies that focus on the development of treatments for genetic disorders,
including Alexion, Sanofi, Shire and Vertex. Treating genetic disorders can be
a desirable prospect, as many genetic disorders are underserved – with only
symptomatic treatments – allowing for high prices. Furthermore, a range of
lucrative incentives such as orphan drug status are available for
pharmaceutical companies to develop treatments for rare diseases, including
extended periods of market exclusivity and tax credits. There is evidence of
more companies moving into this therapy area, and a resultant diversification of
market share.
Key Topics Covered in the Report:
Genetic disorders market research report
Genetic disorders treatment market
Genetic disorders medicine market
Genetic disorder cases worldwide
Genetic disorder Drugs Market
G Protein-Coupled Receptor Modulators Market
Metabolic Enzyme Mediators Market
Key Pipeline Products in Genetic Disorders
Market
Clinical Trials in Genetic disorder Drugs Market
Soliris (eculizumab) Alexion Market
Orkambi (lumacaftor/ivacaftor) Vertex Market
Pulmozyme (dornase alfa) Roche Market
Duchenne Muscular Dystrophy Treatment Market
Lysosomal Storage Disease Treatment Market
Paroxysmal Nocturnal Hemoglobinuria Treatment
Market
To know more about the publication, click on the link
below:
Similar Reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
sales@kenresearch.com
0124-4230204
